Stocks · News reference
Amazon surges 15% on an AWS blowout while Apple sheds nearly $475 billion in value. Yields sit at cycle highs.
Reference details
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
Keep reading
Nvidia’s Unusual Move Please click here for an enlarged chart of NVIDIA Corp (NASDAQ:NVDA). Note the following: The chart shows that NVDA gapped up above the low band of Zone 1 (resistance). RSI on the
Read original at benzingaSince becoming CEO of Berkshire Hathaway, Greg Abel has maintained high concentration in five blue-chip stocks (Apple, American Express, Alphabet, Bank of America, and Coca-Cola), which now represent 60% of the portfolio. While this concentration is largely inherited from Warren Buffett's long-term investments, the article argues that downside risk is manageable given Berkshire's strong financial position. The greater concern is whether Abel can match Buffett's stock selection track record going forward.
Read original at the-motley-foolThe Roundhill Magnificent Seven ETF (MAGS) has underperformed major indexes year-to-date, up only 2% compared to the S&P 500 and Nasdaq's 12% gains. Despite this, investors remain interested due to five of the seven megacap stocks trading at below-average valuations. The concentrated portfolio carries higher volatility risk but offers potential for outperformance when markets rally.
Read original at the-motley-foolNvidia delivered exceptional Q2 results with 106% revenue growth to $96.2 billion, surpassing guidance and Wall Street estimates. The company added nearly $50 billion in revenue—an unprecedented feat for a company of its size—and generated $29.2 billion in adjusted net income, equivalent to Apple's quarterly profit. CEO Jensen Huang forecasted 70% revenue growth for next year, putting Nvidia on track to reach $1 trillion in revenue by fiscal 2029.
Read original at the-motley-foolSubmission supported by data from Phase 3 pivotal AFFIRM studyIf approved, adult Crohn's disease patients will have an additional option for induction of risankizumab which is already approved for intravenous (IV)
Read original at benzingaBillionaire hedge fund manager Ken Griffin's Citadel increased its stake in AbbVie by 547% in Q2, adding 2.7 million shares worth approximately $798 million. The move reflects a defensive investment strategy into a stable dividend stock. AbbVie, a Dividend King with 54 consecutive years of dividend increases, currently yields 2.6% and has 75% of Wall Street analysts rating it as a buy with a median price target of $282.50.
Read original at the-motley-fool